Epidemiology, clinical characteristics and risk factors of COVID-19 among children in Saudi Arabia: a multicenter chart review study

Ahmad AlGhamdi1,2†, Yousef Al Talhi2,3†, Abeer Al Najjar4, Ahmed Sobhi5,6, Alaa Al Juaid1,2,3, Amany Ibrahim5,6, Amer Alshengeti7, Abdulqader Al-Hebshi8, Fayssal Farahat9, Ghaya Al Qurainees8, Manal Al Saif10, Naif Hamdan8, Sameera Al Jehani11, Walaa Al Mansouri1,2,3 and Mona ALDabbagh1,2,3*

Abstract

Background: The Coronavirus Disease 2019 (COVID-19) has affected over 100 million cases worldwide. Children accounted for 1–5% of all cases with less reported symptoms and better prognosis compared to adults. This study aimed to describe the epidemiological characteristics and outcomes of pediatric COVID-19 cases in Saudi Arabia in addition to identifying risk factors associated with disease severity.

Methods: This was a multicenter, cross-sectional retrospective study that included confirmed SARS-CoV-2 infection among pediatric patients (< 14 years) from the time of initial identification in March 2020 to the end of July 2020 in 6 centers across the country. Patients were classified based on clinical severity. Study outcomes included time to recovery, need for invasive ventilation, and mortality. Multivariate logistic regression analysis was conducted to explore factors associated with increased disease severity.

Results: The study enrolled 567 children with (51.5%) were males, and (44.6%) aged from 6 to 14 years old. Asymptomatic patients accounted for 38.98% of the cases: while 319 patients (56%) had mild disease, and 27 patients (4.76%) had moderate-to-severe disease. Only 10 patients (1.76%) required Pediatric Intensive Care Unit admission. The calculated case-fatality was 0.7%. After performing multivariate regression analysis, chronic lung conditions [adjusted OR = 12.73, 95% CI (2.05–79.12)] and decreased red blood cells (RBCs) count [adjusted OR = 2.43, 95% CI (1.09–5.41)] were found to be significant predictors for moderate-to-severe disease (p = 0.006 and 0.030, respectively).

Conclusion: Most COVID-19 cases in the current study had a benign course of illness and carried an excellent prognosis. Children with chronic lung conditions or low RBCs count are at higher risk to develop moderate-to-severe COVID-19 disease.

Keywords: COVID-19, SARS-2, MIS-C coronavirus, Coronaviridae

Introduction

The Coronavirus Disease 2019 (COVID-19) pandemic was announced on 11 March 2020. Since then, the pandemic has been rapidly changing, affecting communities from all over the world. The disease is caused by the emerging Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV2). It is an enveloped, single-strand, positive-sense RNA virus. Like all the viruses that belong
to the family of Coronaviridae, it is transmitted by either direct contact or respiratory droplet. Infections caused by viruses from the Coronaviridae family mainly affect the respiratory and gastrointestinal systems, causing symptoms that vary from simple common cold or pneumonia to acute respiratory distress syndrome (ARDS), multi-organ failure, or death [1]. Nevertheless, SARS-CoV2 has the highest transmissibility among all CoV viruses with $R_0 = 2.5$ (1.8–3.6) [2].

As reported by the World Health Organization (WHO), and as of March 4, 2021, COVID-19 has affected 219 different countries with more than 114 million confirmed cases; the United States of America being the highest contributing country; of which, 2,543,755 cases died due to severe disease [3]. In Saudi Arabia, the disease has affected many regions of the country with a total of 377,383 confirmed cases and reported overall case-fatality rate of 2.22% [4].

Children account for 1 to 5% of all diagnosed COVID-19 cases and appear to be less likely to report symptoms [5, 6]. Data from Saudi Arabia suggest a pediatric incidence of approximately 8%, most of which are identified as part of contact tracing [7]. Of all pediatric age groups, those under the age of 1 year of age are the most vulnerable for COVID-19 infection [5, 8].

Nowadays, epidemiological data regarding pediatric COVID-19 disease are available, and several studies were done in Saudi Arabia [9, 10]. However, more comprehensive studies are still needed for a better understanding of the disease’s nature, course, risk factors, and outcome. This is a multi-center study aimed to describe the epidemiology, clinical presentation, risk factors, and outcome of COVID-19 disease among children in six secondary-to-tertiary health care centers in Saudi Arabia.

Materials and methods

Study design

This was a multicenter, cross-sectional retrospective study. Medical records of pediatric patients (<14 years) were reviewed to describe epidemiological characteristics and outcomes. The study was conducted in 6 centers: Ministry of National Guard Health Affairs (MNGHA) hospitals in Jeddah, Madinah and Alahsa; King Abdulaziz University hospital- Jeddah; King Abdulaziz hospital- Jeddah, and Saudi German hospital- Madinah.

Study subjects

Pediatric patients (aged less than 14 years) with confirmed COVID-19 disease based on positive RT-PCR were included. The study duration was between the first of March to the end of July 2020. The exclusion criteria included any patient who had not done SARS CoV-2 PCR or SARS CoV-2 serology test.

Confirmed COVID-19 cases were defined as: patients with suspected COVID-19 that tested positive for SARS CoV-2 as per testing standards, irrespective of clinical signs and symptoms. WHO classification of COVID-19 clinical severity was utilized where COVID-19 cases are placed into one of the following categories: asymptomatic, mild, moderate, severe, or critical disease. Mild disease includes "Symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia. Moderate disease is defined as pneumonia without age-specific signs and symptoms of severe pneumonia. Severe disease refers to pneumonia cases with an age-specific clinical picture of Acute Respiratory Distress Syndrome (ARDS). Critical disease is defined as the presence of acute respiratory distress syndrome, sepsis, or septic shock [11]. Multisystem Inflammatory Syndrome of Children (MIS-C) cases will be defined as per the WHO case definition [12]. WHO case definition of MIS-C was applied in retrospect to the cases presenting with Kawasaki-like Syndrome before its official release.

Data collection

Data were collected through a web-based generated data collection sheet that was distributed to the contributing centers. Data collection was done through accessing patients’ electronic/paper-based medical records.

The data collection sheet included information related to patients’ demographics, underlying medical condition, clinical manifestations, COVID-19 disease severity classification, laboratory and radiological investigations done, interventions given, and the outcomes (time to recovery, Pediatric or Neonatal Intensive Care Unit (PICU or NICU) admission, need for Positive Pressure Ventilation (PPV), and mortality). Recovery (clinical improvement) was defined as the resolution of symptoms. The need for PPV includes both the use of non-invasive ventilation (C-PAP or Bi-PAP), invasive mechanical ventilation, or Extracorporeal Membrane Oxygenation (ECMO). Mortality related to COVID-19 disease was defined as death within 28 days of the symptoms’ onset.

Statistical analysis

Statistical Package for Social Sciences (SPSS) version 26.00 was used for data analysis. Categorical data were described in numbers and percentages. Continuous data were described in medians and Interquartile ranges-IQR (Q1-Q3). Descriptive statistics were used to compare between patients with mild disease versus patients with moderate-to-severe disease; continuous variables were compared using Mann–Whitney test, and categorical variables were compared using Chi-square with a statistical significance cutoff set at $p < 0.05$. A primary
comparison of outcomes in patients with mild and moderate-to-severe disease was also done.

**Ethical approval**
The study proposal was approved by all corresponding institutional review boards (IRBs), the IRB of King Abdullah International Medical Research Center (KAIMRC), the IRB of Ministry of Health, and the IRB of King Abdulaziz University Hospital. All data, both in soft and hard copies, were maintained and saved within MNGHA premises or the specified study centers and accessed by the research team only.

**Results**
From March to July 2020, 567 patients were enrolled in this study from six different centers in Saudi Arabia. More than half of the patients were males (51.5%). Most patients (44.6%, \( n = 253 \)) aged 6–14 years old. Comorbidities upon presentation were identified in 65 patients (11.4%); chronic lung disease was the frequent co-morbidity and was found in 13 patients. Figure 1 shows the clinical severity of COVID-19 disease where most patients (56%, \( n = 319 \)) had mild disease. Some of the cases in the current study were published elsewhere [10].

Table 1 summarizes the general descriptive statistics for the enrolled patients. Patients were categorized into three groups: asymptomatic, mild disease, and moderate to severe disease. No significant difference was found when comparing males to females in terms of the clinical severity of COVID-19 (\( p = 0.91 \)). Of all asymptomatic, the majority were aged 1–6 years old (46.2%). In mild and moderate-to-severe disease categories, most patients aged 6–14 years old (44.2 and 44.4%, respectively). No significant difference was found across all age groups (\( p = 0.051 \)). Less than one-fifth of patients (18.5%) with moderate-to-severe disease had chronic lung disease compared to 1.8% and 2.8% in the asymptomatic and mild disease groups, respectively (\( p < 0.001 \)). Similar findings were found among patients with chronic heart disease where chronic heart conditions were significantly higher in subjects with moderate-to-severe disease compared to the asymptomatic and mild cases (18.5% vs. 2.8% and 1.8% respectively; \( p < 0.001 \)).

Table 2 illustrates the symptomatology upon presentation. Of 345 symptomatic patients, fever, cough, or shortness of breath accounted for 81.79% (\( n = 283 \)). Fever was the most common presenting symptom followed by cough with 59.54% and 48.27%, respectively. Only one patient (0.29%) presented with an altered level of consciousness.

Table 3 shows the laboratory workup done for symptomatic patients (\( n = 345 \)). Hemoglobin level was significantly lower in the moderate-to-severe disease group compared to mild disease group (median 10.8 vs. 12.60 respectively; \( p = 0.001 \)). Similar findings were
found regarding Red-Blood-Cells (RBCs) count (4.21 vs. 4.69 respectively; \( p = 0.001 \)). On the other hand, International Normalized Ratio (INR) (median = 1.2 vs. 1.1; \( p = 0.004 \)), D-dimer (median = 1.8 vs. 0.60; \( p = 0.018 \)), C-Reactive Protein (CRP) (median = 5.50 vs. 3.0; \( p = 0.001 \)), and Erythrocyte Sedimentation Rate (ESR) (median = 16.50 vs. 5.0; \( p = 0.026 \)) levels were found significantly higher in the moderate-to-severe disease group compared to the mild disease group. Additional file 1 shows case counts per variables that were analyzed in Table 3.

Only ten patients required Intensive Care Unit (ICU) admission; Nine to the PICU and one to the NICU. The profile of ICU patients and the need for ventilatory support is summarized in Table 4; six patients required invasive mechanical ventilation, and 4 patients required noninvasive CPAP. The median and the (IQR) of duration on invasive ventilation were 5 (2–22) days.

Table 5 demonstrates treatment modalities, complications, and outcomes of the included COVID-19 patients; no side effects from the treatment modalities were noticed. From the mild disease group, 94% of the patients received supportive care only in comparison to 40% in moderate to severe disease groups (\( p = 0.001 \)). All patients with the mild disease successfully recovered compared to 85.2% in the moderate-to-severe group. No difference was found regarding time to symptoms resolution in days between mild [median = 6, IQR = (2–9)] and moderate-to severe [median = 8, IQR = (4–9)] disease groups (\( p = 0.345 \)).

Only two complications due to COVID-19 with recovery were observed in the study. One patient aged 12 years and was a known case of epidermolysis bullosa and cardiomyopathy. He presented with fever, cough, and mild shortness of breath with evidence of myocarditis on echocardiography. He was treated in the general ward and recovered after receiving Intravenous Immunoglobulin (IVIG) and Dexamethasone. The other patient aged 6 years and was medically and surgically free. He presented with MIS-C and evidence of bilateral consolidation in chest x-ray and cardiac tamponade on echocardiography. The patient required PICU admission and

### Table 1 General descriptive statistics for the enrolled patient

| Variables                              | Total symptomatic patients = 567 | \( p \)-value$^\text{a}$ |
|----------------------------------------|----------------------------------|--------------------------|
|                                        | Asymptomatic \( n = 221 \) (%)   | Mild disease \( n = 319 \) (%) | Moderate to severe disease$^\text{a}$ \( n = 27 \) (%) |
| Gender                                 |                                  |                          |                             |
| Female                                 | 113 (51.1)                       | 164 (51.4)               | 15 (55.6)                  | 0.909 |
| Male                                   | 108 (48.9)                       | 155 (48.6)               | 12 (44.4)                  |      |
| Age groups                             |                                  |                          |                             |
| Less than 1 month                      | 0                                | 5 (1.6)                  | 1 (3.7)                    | 0.051 |
| 1–11 months                            | 19 (8.6)                         | 45 (14.1)                | 6 (22.2)                   |      |
| 1–6 years                              | 102 (46.2)                       | 128 (40.1)               | 8 (29.6)                   |      |
| > 6 years                              | 100 (45.2)                       | 141 (44.2)               | 12 (44.4)                  |      |
| Co-morbidities                         |                                  |                          |                             |
| Chronic lung conditions$^\text{b}$     | 4 (1.8)                          | 9 (2.8)                  | 5 (18.5)                   | 0.0001 |
| Diabetes Mellitus-type 1               | 3 (1.4)                          | 2 (0.6)                  | 1 (3.7)                    | NA    |
| Hypertension                           | 0                                | 3 (0.9)                  | 0                          | NA    |
| Chronic heart disease                  | 2 (0.9)                          | 8 (2.5)                  | 5 (18.5)                   | 0.0001 |
| Human Immunodeficiency Virus (HIV) Infection | 1 (0.5)                     | 2 (0.6)                  | 0                          | NA    |
| Epilepsy                               | 1 (0.5)                          | 3 (0.9)                  | 1 (3.7)                    | NA    |
| Hgb and blood-enzymes defects          | 1 (0.5)                          | 3 (0.9)                  | 1 (3.7)                    | NA    |
| Active malignancy                      | 4 (1.8)                          | 0                        | 2 (7.4)                    | NA    |
| Genitourinary diseases                 | 2 (0.9)                          | 2 (0.6)                  | 0                          | NA    |
| Primary immunodeficiency               | 0                                | 0                        | 1 (3.7)                    | NA    |
| On immune- modulator/suppressor drugs  | 2 (0.9)                          | 2 (0.6)                  | 2 (7.4)                    | NA    |
| On chemotherapy                        | 4 (1.8)                          | 0                        | 1 (3.7)                    | NA    |

$^a$ \( p \)-value for variables with expected count < 5 in more than 25% of the cells was displayed as NA- (Not Applicable-relevant)

$^a$ It included sepsis pneumonia and critical disease (Acute Respiratory Distress Syndrome (ARDS), Sepsis, or Septic Shock)

$^b$ It included patients with asthma/hype Active Airway Disease (\( n = 11 \)), ventilator-dependent Cerebral Palsy (\( n = 1 \)), and Bronchiolitis Olblitans (\( n = 1 \))
Table 2 The reported symptomatology of COVID-19 in the multicenter studya

| Variables                        | n = 346 (%) |
|----------------------------------|-------------|
| **Fever, cough, or shortness of breath** |             |
| Fever                            | 283 (81.79) |
| Cough                            | 206 (59.54) |
| Diarrhea                         | 167 (48.27) |
| Nausea/Vomiting                  | 71 (20.52)  |
| Anorexia/Decreased feeding       | 64 (18.50)  |
| Rhinorrhea                        | 55 (15.90)  |
| Fatigue/decreased activity       | 50 (14.45)  |
| Shortness of breath              | 48 (13.87)  |
| Headache                         | 39 (11.27)  |
| Sore throat                      | 31 (8.96)   |
| Myalgia                          | 28 (8.09)   |
| Anosmia                          | 20 (5.78)   |
| Abdominal pain                   | 11 (3.18)   |
| Abnormal movement                | 7 (2.02)    |
| Chest pain                       | 7 (2.02)    |
| Ageusia                          | 3 (0.87)    |
| Kawasaki-like Syndrome           | 3 (0.87)    |
| Altered level of consciousness   | 2 (0.58)    |
| Anorexia/Decreased feeding       | 2 (0.58)    |
| Altered level of consciousness   | 1 (0.29)    |

a 221 patients (39%) were asymptomatic at presentation

received IVIG, Dexamethasone, Favipiravir, Hydroxychloroquine, and Azithromycin. He was later discharged in good condition after being hospitalized for 10 days.

A total of four patients (14.8%) in the moderate to severe group died with an overall case-fatality rate of 0.7%. One patient aged 17 months and was having severe aplastic anemia and pulmonary tuberculosis on treatment. He presented with severe pneumonia that was complicated by ARDS; he subsequently died from septic shock. The second patient aged 4 months and was under investigation for inborn error of metabolism. He was tested positive for COVID-19, but his death was most likely attributed to his metabolic disease. The third patient aged 6 months and was diagnosed with spinal muscular atrophy (SMN1-EXON7 deletion); he was severely hypotonic and was on limited code status before developing COVID-19. The fourth patient aged 11 years and was medically and surgically free. He presented with a picture of MIS-C. The patient later developed ARDS and subsequently died.

Chronic lung conditions, chronic heart conditions, hemoglobin level, RBCs count, and CRP level were entered into a multivariate regression analysis to identify risk factors/predictors for moderate-to-severe COVID-19 (Table 6). After controlling for potential confounders, only chronic lung conditions [adjusted OR = 12.72, 95% CI (2.05–79.12), p = 0.006] and low RBCs count [adjusted OR = 0.41, 95% CI (0.19–0.92), p = 0.30] were significant predictors for moderate-to-severe COVID-19 in the model.

Discussion

This multi-center study described the epidemiology, clinical presentation, and outcomes of pediatric COVID-19 in Saudi Arabia. The majority (95%) of the patients were asymptomatic or had mild disease. Almost half of the patients were > 6 years of age, including those with moderate-to-severe disease. Most patients received supportive care only; few patients required admission to the ICU, and the fatality rate was very low. The study also found that having an underlying chronic lung condition and reduced RBCs are risk factors for developing moderate-to-severe disease.

The epidemiology of COVID-19 in Saudi Arabia and the Gulf region was described in multiple studies. For example, Al Yazidi et al. found in a multicenter cohort from Oman that 68% of the documented cases (n = 56) had uncomplicated COVID-19; of which 13% were admitted to the PICU. Only one patient required invasive mechanical ventilation, and no mortality was reported [13]. Alharbi et al. conducted a comprehensive, single-center study on COVID-19 in children from Riyadh; 742 patients with positive SARS-2 PCR were included, of which 60% were > 5 years of age. 71 patients (9.6%) required hospitalization while 12 patients required PICU transfer with only three reported deaths [9].

Data from worldwide reports were included in a systematic review on childhood COVID-19 with a sample size of 1124 cases; severe/critical disease occurred in < 3.5% of the cases, with a single reported death [14]. Similarly, a recent multicenter report from Europe suggested that asymptomatic cases account for 16% of the identified cases with 8% severe diseases and a fatality rate of 0.69% [15]. Another study published from China suggested that 86% of all early COVID-19 infections remained undiagnosed and these cases may have had a major role in infection transmission [16].

Although it did not reach statistical significance, this study suggests that almost half of the confirmed COVID-19 cases, including those with more severe disease, were more than 6 years of age. This finding was in agreement with other Saudi data [9]. Nonetheless, most international data suggested that those less than 1 year of age were the most vulnerable group [17, 18].

The current study found a similarly low rate of severe disease and case fatality rate. Preliminary evidence suggests that children become infected with SARS-CoV-2 just like adults; however, they are less likely to express symptoms or develop severe disease and accordingly are less likely to die. This could be attributed to the
differences in the function of the adult immune system and/or differences in the cellular receptor expression among patients with SARS-CoV2- such as Angiotensin Converting Enzyme-2 (ACE-2) receptor [8, 19]. Another proposed explanation would be related to repeated viral exposures in children which strengthens the immune system to fight SARS CoV-2 [20]. On the other hand, the high rate of asymptomatic cases in the current study could be attributed to the meticulous contact tracing that was undertaken in the country. Nonetheless, the role of children in infection transmission escalating remains unclear.

The role of underlying medical conditions as risk factors for severe COVID-19 in children was investigated in few studies. Graff et al. reported that immunocompromising conditions, gastrointestinal conditions, diabetes, and asthma are predictors for hospital admission. In addition, asthma and gastrointestinal conditions were associated with increased odds of requiring respiratory support. The current study found that those with

### Table 3: Investigations done to the symptomatic patients in the multicenter study

| Variables                                      | Total symptomatic patients = 346 | p-value†   |
|------------------------------------------------|----------------------------------|------------|
|                                               | Mild disease                     | Moderate to severe disease§ |           |
|                                               | n = 319                          | n = 27     |           |
| Median Hgb in gm/dL (Q1-Q3)                   | 12.60 (11.60–13.5)               | 10.80 (8.90–12.7) | 0.001     |
| Median RBCs × 10^{12}/L (Q1-Q3)               | 4.69 (4.31–5.07)                 | 4.21 (3.69–4.65) | 0.001     |
| Median Neutrophils × 10^9/L (Q1-Q3)          | 2.68 (1.35–5.27)                 | 2.99 (1.31–6.2) | 0.754     |
| Median Lymphocytes × 10^9/L (Q1-Q3)          | 3.03 (1.79–5.16)                 | 3.00 (3.01–4.26) | 0.838     |
| Median Basophils × 10^9/L (Q1-Q3)            | 0.04 (0.02–0.09)                 | 0.05 (0.02–0.08) | 0.847     |
| Median Eosinophils × 10^9/L (Q1-Q3)          | 0.15 (0.08–0.35)                 | 0.1 (0.03–0.208) | 0.119     |
| Median Monocytes × 10^9/L (Q1-Q3)            | 0.71 (0.48–1.18)                 | 0.76 (0.49–1.87) | 0.569     |
| Median Platelets × 10^12/L (Q1-Q3)           | 305 (298–398)                    | 315 (146.50–399.5) | 0.510     |
| Median Platelets/lymphocyte ratio (Q1-Q3)    | 93.27 (61.17–157.61)             | 87.55 (60.29–147.42) | 0.656     |
| Median Neutrophil/lymphocyte ratio (Q1-Q3)   | 0.86 (0.41–1.81)                 | 1.12 (0.46–2.43) | 0.588     |
| Median PTT/APTT in seconds (Q1-Q3)           | 32.80 (31–34)                    | 33.2 (31.8–41.56) | 0.189     |
| Median INR in seconds (Q1-Q3)                | 1.1 (1–1.2)                      | 1.2 (1–1.4) | 0.004     |
| Median Fibrinogen in g/L (Q1-Q3)             | 3.07 (1.3–3.59)                  | 3.62 (2.55–8.63) | 0.808     |
| Median D-dimer in mg/L (Q1-Q3)               | 0.6 (0.28–1.05)                  | 1.08 (0.61–5.89) | 0.018     |
| Median CK in IU/L (Q1-Q3)                    | 86 (44.25)                       | 46 (115) | 0.452     |
| Median SrCr in umol/L (Q1-Q3)                | 37.5 (30.13–46)                  | 35 (16–43) | 0.013     |
| Median BUN in mmol/L (Q1-Q3)                 | 3.80 (2.90–6.1)                  | 4.5 (3.35–5.23) | 0.445     |
| Median ALT in U/L (Q1-Q3)                    | 20 (14–31.5)                     | 21 (15–37) | 0.471     |
| Median AST in U/L (Q1-Q3)                    | 32.50 (25–43.75)                 | 32 (21.5–37) | 0.767     |
| Median CRP in mg/L (Q1-Q3)                   | 3.0 (1–5.2)                      | 5.3 (3.14–66.15) | 0.001     |
| Median ESR in mm/hr (Q1-Q3)                  | 5 (2–10)                         | 16.5 (11.75–55.75) | 0.026     |
| Chest x-ray (CXR) findings                   |                                   |           |           |
| Not done                                      | 226 (70.8%)                      | 0         | NA        |
| Normal                                        | 87 (27.3%)                       | 5 (18.5%) |           |
| Lobar infiltration                            | 4 (1.3%)                         | 8 (29.6%) |           |
| Broncho-pneumonic infiltrations              | 1 (0.3%)                         | 8 (29.6)  |           |
| Bilateral consolidation                      | 1 (0.3%)                         | 6 (2.2)   |           |
| Chest CT scan                                 |                                   |           | NA        |
| Not Done                                      | 317 (99.4%)                      | 25 (92.6%) |           |
| Done (Normal)                                 | 2 (0.6%)                         | 0         |           |
| Done (abnormal)                               | 0                                 | 2 (7.4%)  |           |

† p-value for categorical variables with expected count < 5 in more than 25% of the cells was displayed as NA- (Not Applicable-relevant). P-value for scale variables was calculated using Mann-Whitney U test.

§ It included severe pneumonia and critical disease (Acute Respiratory Distress Syndrome (ARDS), Sepsis, or Septic Shock.)
underlying lung conditions, for which the majority had asthma/hyperactive airway disease, were more likely to develop moderate-to-severe disease. However, we could not demonstrate any further association with any other comorbidities. This could be explained by the very small number of cases with such comorbidities [17].

A meta-analysis also looked at the effect of anemia and iron metabolism in COVID-19 and found that severe cases, compared to moderate COVID-19 cases, had significantly lower hemoglobin and RBCs count, and higher ferritin level. It is hypothesized that the innate immune system in the acute phase of infection may aim to decrease iron bioavailability in order to prevent an expanding viral load. This results in the activation of hepcidin, sequestration of intracellular iron, increased ferritin levels, drop-in hemoglobin level, and resultant hypoxia [21]. These findings are similar to ours where moderate-to-severe disease group had significantly lower hemoglobin and RBCs in comparison to the mild group. Nevertheless, after performing multivariate analysis, only RBCs count was found to be a significant predictor for moderate-to-severe COVID-19.

In addition, the prognostic role of elevated inflammatory markers and Prothrombin time was reported in many studies. A meta-analysis conducted by Elshazli et al. reported that elevated CRP, procalcitonin, ESR,

### Table 4
Clinical profile of patients who required Intensive Care Unit (ICU) admission

| Variables                                    | n = 10 |
|----------------------------------------------|--------|
| Types of ventilatory support                 |        |
| Invasive pressure control                    | 2 (20%)|
| Invasive pressure support                    | 1 (10%)|
| Invasive SIMV                                | 1 (10%)|
| Invasive volume control                      | 2 (20%)|
| Non-invasive C-PAP                           | 4 (40%)|
| Median Duration on Invasive Ventilation* (Q1-Q3) | 5 (2–22) |

* One patient was still ventilated beyond the study period

### Table 5
Treatment, complication, and Outcomes of COVID-19 in terms of disease severity

| Variables                              | Total symptomatic patients = 346 | p-value
|----------------------------------------|----------------------------------|---------|
|                                        | Mild disease                     | moderate to severe* |
|                                        | n = 319                          | n = 27 |
| **Supportive Care Only**               |                                  |         |
| (e.g., hydration, temperature control, etc.) | 301 (94.4)                      | 11 (40.7) | 0.0001 |
| **Antimicrobials**                      |                                  |         |
| No antimicrobial used                  | 302 (94.7)                       | 17 (63) | 0.0001 |
| Hydroxychloroquine/Chloroquine         | 1 (0.3)                          | 3 (11.1) | NA |
| Hydroxychloroquine/Chloroquine + any macrolide | 7 (2.2)                      | 5 (18.5) | 0.0001 |
| Azithromycin alone                     | 9 (2.8)                          | 2 (7.4) | 0.192 |
| **Anticoagulant therapy**               |                                  |         |
| Unfractionated Heparin                 | 1 (0.3)                          | 0 | NA |
| **Antivirals used:**                   |                                  |         |
| No antiviral used                      | 319 (100)                        | 23 (85.2) | NA |
| Umifenovir                             | 0                                | 0 | NA |
| Favipiravir                            | 0                                | 3 (11.1) | NA |
| Interferon β-1a                        | 0                                | 1 (3.7) | NA |
| **Biologicals used:**                  |                                  |         |
| Tocilizumab                            | 0                                | 0 | NA |
| Convalescent Plasma Therapy            | 0                                | 1 (3.7) | NA |
| **Complications**                      |                                  |         |
| Myocarditis                            | 0                                | 1 (3.7) | NA |
| Massive pericardial effusion           | 0                                | 1 (3.7) | NA |
| **Outcome**                            |                                  |         |
| Recovery                               | 319 (100)                        | 23 (85.2) | NA |
| Death                                  | 0                                | 4 (14.8) | NA |

* p-value for variables with expected count < 5 in more than 25% of the cells was displayed as NA- (Not Applicable-irrelevant)  
* overall p-value for all variables is NA  
* It included severe pneumonia and critical disease (Acute Respiratory Distress Syndrome (ARDS), Sepsis, or Septic Shock)
and prothrombin time were significantly associated with increased odds of severe disease progression [22]. These findings were compatible with ours in the univariate analysis. Yet, after performing multivariate regression analysis, none of the inflammatory and coagulation markers showed a significant increase in the odds for moderate-to-severe disease.

Gracia Salido et al. reported 74 patients with PICU admissions due to severe COVID-19; 60% fulfilled the criteria of MIS-C diagnosis. Lopinavir-ritonavir was used in 40% of patients. No difference was noticed in the outcome if antiviral treatment was given [23]. In the current study, two patients were diagnosed with MIS-C. The first patient was admitted to the PICU and received extensive management and recovered after 10 days. The second patient developed severe ARDS and died. In addition, the use of antivirals was very limited to certain cases and no effect on the outcome was observed; all the patients who received antiviral treatment died.

Conclusion
Most COVID-19 cases in the current study had a benign course of illness and carried an excellent prognosis, which is comparable to most studies worldwide. Chronic lung disease and decreased RBCs were found to be significant predictors for moderate-to-severe COVID-19 presentation. No recommendation could be made regarding the use of antivirals and immunomodulatory therapy due to the low number of severe cases and mortality. There is still a need for further studies identifying the contributing risk factors and best therapeutic modalities in pediatric COVID-19.

Limitations
Although the current study provided a sufficient sample size, it was limited by the retrospective design, the limited number of patients with moderate-to-severe disease, and the low mortality rate. This led to major constraints in the analysis due to missing laboratory investigations and diagnostic workup. In addition, the study could not assess the effect of using antivirals or immunomodulatory agents on the outcome. Future large prospective studies examining risk factors for severe COVID-19 in children are warranted to understand the full picture of pediatric COVID-19. In addition, more robust data on the best treatment modalities are strongly indicated.

Abbreviations
COVID-19: The Coronavirus Disease 2019; SARS-CoV2: Severe Acute Respiratory Syndrome Coronavirus-2; WHO: World Health Organization; MNGHA: Ministry of National Guard Health Affairs; ARDS: Acute Respiratory Distress Syndrome; MIS-C: Multisystem inflammatory syndrome of Children; PICU: Pediatric Intensive Care Unit; NICU: Neonatal Intensive Care Unit; PPV: Positive Pressure Ventilation; ECMO: Extracorporeal Membrane Oxygenation; SPSS: Statistical Package for Social Sciences; IQR: interquartile ranges (Q1-Q3); IRB: Institutional Review Board; KAIMRC: King Abdullah International Medical Research Center; RBCs: Red Blood Cells; INR: International Normalized Ratio; CRP: C-Reactive Protein; ESR: Erythrocyte Sedimentation Rate; IVIG: Intravenous Immune Globulin; OR: Odds ratio; CI: Confidence interval; ACE-2: Angiotensin-Converting Enzyme-2.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12887-021-02959-8.

Table 6  Multivariate analyses for risk factors/predictors associated with moderate-to-severe COVID-19 in children

| Variables                          | Symptomatic patients |                  | Crude Odds Ratio<sup>b</sup> (CI) | Adjusted Odds Ratio<sup>b</sup> (CI) | p-value |
|------------------------------------|----------------------|------------------|-----------------------------------|-------------------------------------|---------|
|                                    | Mild disease <br>n = 91 | Moderate-to-severe disease <br>n = 25 |                                   |                                     |         |
| Chronic lung conditions<sup>c</sup> | 3 (3.30%)             | 4 (16%)          | 5.59 (1.16–26.88)                 | 12.72 (2.05–79.12)                  | 0.006   |
| Chronic heart disease              | 5 (5.49%)             | 5 (20%)          | 4.30 (1.14–16.29)                 | 2.86 (0.65–12.57)                   | 0.165   |
| Median Hgb in gm/dL <br>(Q1-Q3)    | 12.7 (11.7–13.4)      | 10.4 (8.75–12.9) | 1.33 (1.1–1.61)                   | 1.19 (0.92–1.56)                    | 0.193   |
| Median Red-Blood-Cells count x 10<sup>12</sup>/L <br>(Q1-Q3) | 4.7 (4.4–5.1)         | 4.21 (3.48–4.72) | 2.7 (1.49–4.76)                   | 2.44 (1.09–5.26)                    | 0.030   |
| Median CRP in mg/L <br>(Q1-Q3)     | 3 (0.9–5.8)           | 5.5 (3.14–66.15) | 1.009 (1.002–1.02)                | 1 (0.998–1.015)                     | 0.129   |

<sup>a</sup> Multiple cases had missing values given the retrospective nature of the study. The analysis was limited to the cases where all of the above-mentioned variables were available.

<sup>b</sup> Odd ratios for Hgb and RBCs were inverted for clarity.

<sup>c</sup> It included patients with asthma/hyper-active airway disease (n = 11), ventilator-dependent Cerebral Palsy (n = 1), and Bronchiolitis Obliterans (n = 1)
Acknowledgments
We would like to thank Mr. Yassir abidalkareem Alabweeni from Infection prevention and control department at Prince Mohammad bin Abdulaziz Hospital for his assistance in organizing COVID-19 cases that were identified in the center. We would like also to extend our gratitude to the data collector from King Abdulaziz medical City- Jeddah for their dedicated efforts and commitment.

Authors’ contributions
All authors contributed majorly to the writing of the manuscript. Mona AlDabbagh designed the study. The data was collected by or under the supervision of the authors. Yousef Al Talhi, Mona AlDabbagh, and Faysal Farahat analyzed and interpreted the data. Ahmad AlGhamdi and Yousef Al Talhi drafted the manuscript. All authors read and approved the final manuscript.

Funding
This study received no financial support from local or international institutions.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
Patients’ privacy and confidentiality were completely preserved. No personal identifier or information was collected or stored. All methods were performed in accordance with the relevant guidelines and regulations. Experimental protocols were also approved by the IRB of KAIMRC, the IRB of Ministry of Health, and the IRB of King Abdulaziz University Hospital. The requirement for informed consent was waived by the IRB of KAIMRC, the IRB of Ministry of Health, and the IRB of King Abdulaziz University Hospital.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Pediatrics, King Abdulaziz Medical City, P.O. Box: 65362, Jeddah 21556, Saudi Arabia. 2 King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia. 3 King Saud bin Abdulaziz University for Health Sciences, P.O. Box: 65362, Jeddah 21556, Saudi Arabia. 4 Department of Pediatrics, King Abdulaziz University, Jeddah, Saudi Arabia. 5 Pediatric Department, Saudi German Hospital, Almadinah, Saudi Arabia. 6 Pediatric Department, Cairo University, Cairo, Egypt. 7 Department of Pediatrics, College of Medicine, Taibah University, Almadinah, Saudi Arabia. 8 Department of Pediatrics, Prince Mohammad bin Abdulaziz Hospital, Almadinah, Saudi Arabia. 9 Infection Prevention and Control Program, King Abdulaziz Medical City, Riyadh, Saudi Arabia. 10 Department of Pediatrics, King Abdulaziz Hospital, King Abdullah, International Medical Research Center, P.O. Box: 2477, Al-Ahsa 31982, Saudi Arabia. 11 Department of Pediatric, King Abdulaziz Hospital, P.O Box: 22421, Jeddah 21470, Saudi Arabia.

Received: 3 April 2021 Accepted: 7 October 2021 Published online: 12 February 2022

References
1. How COVID-19 Spreads [https://www.cdc.gov/coronavirus/2019-ncov/ prevent-getting-sick/how-covid-spreads.html ]. Accessed 15 Feb 2021.
2. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238–44.
3. WHO Coronavirus (COVID-19) Dashboard [https://covid19.who.int/]. Accessed 4 Mar 2021.
4. (COVID-19) Disease Interactive Dashboard [https://covid19.cdc.gov/sa/daily-updates/]. Accessed 5 Mar 2021.
5. Team CC-R. Coronavirus disease 2019 in children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422–6.
6. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39(5):355–68.
7. Alyami MH, Nasr YA, Obaid MA, Alwafi H, Alyami HS. Epidemiology of COVID-19 in the Kingdom of Saudi Arabia: an ecological study. Front Public Health. 2020;8:506.
8. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6).
9. Alharbi M, Kazzaz YM, Hameed T, Alqanatish J, Alkhalfa H, Alsadoon A, Alayed M, Hussien SA, Al Shaalan M, Al Johani SM. SARS-CoV-2 infection in children, Clinical Characteristics, Diagnostic Findings and Therapeutic Interventions at a Tertiary Care Center in Riyadh, Saudi Arabia. J Infect Public Health. 2021;14(4):446-53.
10. Kani JA, Shalaby MA, Albanna AS, Alahmadi TS, Sukkar SA, MohamedNur HA, et al. Coronavirus disease in children: a multicentre study from the Kingdom of Saudi Arabia. J Infect Public Health. 2021;14(4):543–9.
11. Clinical management of COVID-19: interim guidance [https://www.who.int/publications/i/item/clinical-management-of-covid-19]. Accessed 4 Mar 2021.
12. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 [https://www.who-news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19]. Accessed 5 Mar 2021.
13. Al Yazidi LS, Al Hina Z, Al Wail B, Al Hashami H, Al Reesee M, Al Othman F, et al. Epidemiology, characteristics and outcome of children hospitalized with COVID-19 in Oman: a multicenter cohort study. Int J Infect Dis. 2021;104:655–60.
14. de Souza TH, Nadal JA, Nogueira RIN, Pereira RM, Brandao MB. Clinical manifestations of children with COVID-19: a systematic review. Pediatr Pulmonol. 2020;55(8):1892–9.
15. Gotzinger F, Santiago-Garcia B, Noguera-Julian A, Lanaspa M, Lancell L, Calo Carducci F, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653–61.
16. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020;368(6490):489–93.
17. Graff K, Smith C, Silvers I, Jung S, Curran-Hays S, Jarjour J, et al. Risk factors for severe COVID-19 in children. Pediatr Infect Dis J. 2021;40(4):e137-45.
18. Tsaibouri S, Makis A, Kosmeri C, Somou E. Risk factors for severity in children with coronavirus disease 2019: a comprehensive literature review. Pediatr Clin N Am. 2021;68(1):321–38.
19. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–3.
20. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088–95.
21. Taneri PE, Gomez-Ochoa SA, Llanaj E, Rugundin RF, Rojas LZ, Roa-Diaz ZM, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(8):763–73.
22. Elshazli RM, Toraih EA, Elgaml A, El-Mowafy M, El-Mesery M, Amin MN, et al. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: a meta-analysis of 6320 patients. PLoS One. 2020;15(8):e0238160.
23. Garcia-Salido A, de Carlos Vicente JC, Belda Hofheinz S, Balcells Ramirez J, Stocker Barrio M, Leoz Gordillo I, et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care. 2020;24(1):666.